Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility

Marion Mortamais, Jessica A. Ash, John Harrison, Jeffrey Kaye, Joel Kramer, Christopher Randolph, Carine Pose, Bruce Albala, Michael Ropacki, Craig W. Ritchie, Karen Ritchie

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Significant progress has been made in characterizing the biological changes occurring in preclinical Alzheimer's disease (AD). Cognitive dysfunction has been viewed, however, as a late-stage phenomenon, despite increasing evidence that changes may be detected in the decades preceding dementia. In the absence of comprehensive evidence-based guidelines for preclinical cognitive assessment, longitudinal cohort and neuroimaging studies have been reviewed to determine the temporal order and brain biomarker correlates of specific cognitive functions. Episodic memory decline was observed to be the most salient cognitive function, correlating with high levels of amyloid deposition and hypoconnectivity across large-scale brain networks. Prospective studies point to early decline in both episodic and semantic memory processing as well as executive functions in the predementia period. The cognitive tests have, however, been principally those used to diagnose dementia. New procedures are required which target more finely the medial temporal lobe subregions first affected by clinically silent AD pathology.

Original languageEnglish
Pages (from-to)468-492
Number of pages25
JournalAlzheimer's and Dementia
Volume13
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017

Cite this

Mortamais, M., Ash, J. A., Harrison, J., Kaye, J., Kramer, J., Randolph, C., ... Ritchie, K. (2017). Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. Alzheimer's and Dementia, 13(4), 468-492. https://doi.org/10.1016/j.jalz.2016.06.2365
Mortamais, Marion ; Ash, Jessica A. ; Harrison, John ; Kaye, Jeffrey ; Kramer, Joel ; Randolph, Christopher ; Pose, Carine ; Albala, Bruce ; Ropacki, Michael ; Ritchie, Craig W. ; Ritchie, Karen. / Detecting cognitive changes in preclinical Alzheimer's disease : A review of its feasibility. In: Alzheimer's and Dementia. 2017 ; Vol. 13, No. 4. pp. 468-492.
@article{76fe9e504af8451a88fee1135c33886e,
title = "Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility",
abstract = "Significant progress has been made in characterizing the biological changes occurring in preclinical Alzheimer's disease (AD). Cognitive dysfunction has been viewed, however, as a late-stage phenomenon, despite increasing evidence that changes may be detected in the decades preceding dementia. In the absence of comprehensive evidence-based guidelines for preclinical cognitive assessment, longitudinal cohort and neuroimaging studies have been reviewed to determine the temporal order and brain biomarker correlates of specific cognitive functions. Episodic memory decline was observed to be the most salient cognitive function, correlating with high levels of amyloid deposition and hypoconnectivity across large-scale brain networks. Prospective studies point to early decline in both episodic and semantic memory processing as well as executive functions in the predementia period. The cognitive tests have, however, been principally those used to diagnose dementia. New procedures are required which target more finely the medial temporal lobe subregions first affected by clinically silent AD pathology.",
keywords = "Alzheimer's disease, Cognition, Diagnosis, Neuropsychology, Preclinical markers",
author = "Marion Mortamais and Ash, {Jessica A.} and John Harrison and Jeffrey Kaye and Joel Kramer and Christopher Randolph and Carine Pose and Bruce Albala and Michael Ropacki and Ritchie, {Craig W.} and Karen Ritchie",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.jalz.2016.06.2365",
language = "English",
volume = "13",
pages = "468--492",
journal = "Alzheimers & Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "4",

}

Mortamais, M, Ash, JA, Harrison, J, Kaye, J, Kramer, J, Randolph, C, Pose, C, Albala, B, Ropacki, M, Ritchie, CW & Ritchie, K 2017, 'Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility' Alzheimer's and Dementia, vol. 13, no. 4, pp. 468-492. https://doi.org/10.1016/j.jalz.2016.06.2365

Detecting cognitive changes in preclinical Alzheimer's disease : A review of its feasibility. / Mortamais, Marion; Ash, Jessica A.; Harrison, John; Kaye, Jeffrey; Kramer, Joel; Randolph, Christopher; Pose, Carine; Albala, Bruce; Ropacki, Michael; Ritchie, Craig W.; Ritchie, Karen.

In: Alzheimer's and Dementia, Vol. 13, No. 4, 01.04.2017, p. 468-492.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Detecting cognitive changes in preclinical Alzheimer's disease

T2 - A review of its feasibility

AU - Mortamais, Marion

AU - Ash, Jessica A.

AU - Harrison, John

AU - Kaye, Jeffrey

AU - Kramer, Joel

AU - Randolph, Christopher

AU - Pose, Carine

AU - Albala, Bruce

AU - Ropacki, Michael

AU - Ritchie, Craig W.

AU - Ritchie, Karen

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Significant progress has been made in characterizing the biological changes occurring in preclinical Alzheimer's disease (AD). Cognitive dysfunction has been viewed, however, as a late-stage phenomenon, despite increasing evidence that changes may be detected in the decades preceding dementia. In the absence of comprehensive evidence-based guidelines for preclinical cognitive assessment, longitudinal cohort and neuroimaging studies have been reviewed to determine the temporal order and brain biomarker correlates of specific cognitive functions. Episodic memory decline was observed to be the most salient cognitive function, correlating with high levels of amyloid deposition and hypoconnectivity across large-scale brain networks. Prospective studies point to early decline in both episodic and semantic memory processing as well as executive functions in the predementia period. The cognitive tests have, however, been principally those used to diagnose dementia. New procedures are required which target more finely the medial temporal lobe subregions first affected by clinically silent AD pathology.

AB - Significant progress has been made in characterizing the biological changes occurring in preclinical Alzheimer's disease (AD). Cognitive dysfunction has been viewed, however, as a late-stage phenomenon, despite increasing evidence that changes may be detected in the decades preceding dementia. In the absence of comprehensive evidence-based guidelines for preclinical cognitive assessment, longitudinal cohort and neuroimaging studies have been reviewed to determine the temporal order and brain biomarker correlates of specific cognitive functions. Episodic memory decline was observed to be the most salient cognitive function, correlating with high levels of amyloid deposition and hypoconnectivity across large-scale brain networks. Prospective studies point to early decline in both episodic and semantic memory processing as well as executive functions in the predementia period. The cognitive tests have, however, been principally those used to diagnose dementia. New procedures are required which target more finely the medial temporal lobe subregions first affected by clinically silent AD pathology.

KW - Alzheimer's disease

KW - Cognition

KW - Diagnosis

KW - Neuropsychology

KW - Preclinical markers

UR - http://www.scopus.com/inward/record.url?scp=85007349421&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.06.2365

DO - 10.1016/j.jalz.2016.06.2365

M3 - Review article

VL - 13

SP - 468

EP - 492

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

IS - 4

ER -